文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-PSMA-1007 PET/CT与68Ga-PSMA-11 PET/CT在中高危前列腺癌初始分期中的比较

Comparison of 18 F-PSMA-1007 PET/CT With 68 Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2022-10-14

本研究前瞻性纳入40例未经治疗、活检证实的中高危前列腺癌患者,每例均在2周内先后接受68Ga-PSMA-11与18F-PSMA-1007 PET/CT。两种示踪剂对前列腺内病灶检出及PET分期一致,主要病灶SUVmax无显著差异,18F-PSMA-1007仅额外检出少数淋巴结和骨病灶。作者认为18F-PSMA-1007 PET/CT在检出原发及转移病灶方面与68Ga-PSMA-11 PET/CT相当。

要点

  • 40例中高危前列腺癌患者中两种示踪剂均检出前列腺内病灶,PET-based T分期一致。
  • 主要前列腺病灶中位SUVmax 18F-PSMA-1007 19.9 vs 68Ga-PSMA-11 19.4(P=0.127,n=40),无显著差异。
  • 18F-PSMA-1007额外检出少数淋巴结(n=3)和骨髓/骨病灶(n=7),可能上调2/5例患者PET-based M分期。

核心结论

  • 作者认为18F-PSMA-1007 PET/CT在检出前列腺癌原发及转移病灶方面与68Ga-PSMA-11 PET/CT相当。

研究设计与样本

  • 前瞻性纳入40例未经治疗、活检证实的中危或高危前列腺癌患者。
  • 每例患者均在2周内接受68Ga-PSMA-11与18F-PSMA-1007 PET/CT检查。
  • 评估内容包括病灶数目与特征、SUVmax、miPSMA评分及PET-based分期。

主要发现

  • 两种示踪剂均检出全部患者的前列腺内病灶,PET-based T分期一致。
  • 主要PSMA阳性前列腺病灶中位SUVmax:18F-PSMA-1007 19.9 vs 68Ga-PSMA-11 19.4(P=0.127,n=40),无显著差异。
  • 31/40(77.5%)患者两种示踪剂的前列腺miPSMA评分相似(加权κ=0.71)。
  • 23/40(57.5%)患者两种示踪剂均检出区域淋巴结(n=171);2例患者18F-PSMA-1007额外检出3枚PET阳性区域淋巴结,未改变PET-based N分期。
  • 17/40患者两种示踪剂一致检出区域外淋巴结(n=123),3/40患者一致检出内脏转移灶(n=18)。

关键数值与推荐

  • 14/40(35%)患者两种示踪剂均检出PET阳性骨髓及骨骼转移灶(n=71)。
  • 5/14患者18F-PSMA-1007额外检出7处骨髓及骨骼病灶,其中2/5患者PET-based M分期可能上调。
  • 两种示踪剂在区域病灶检出方面均显示极佳的阅片者间一致性。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to compare 18 F-PSMA-1007 PET/CT with 68 Ga-PSMA-11 PET/CT for initial staging in intermediate- and high-risk prostate cancer (PCa) patients. METHODS: Forty treatment-naive, biopsy-proven, intermediate- or high-risk PCa patients were prospectively recruited. Each patient underwent PET/CT with 68 Ga-PSMA-11 and 18 F-PSMA-1007 (within 2 weeks). Assessment of both set of images included delineating number and characteristics of lesions, measurement of tracer uptake (SUV max ), miPSMA scoring, and PET-based stage categorization. RESULTS: Intraprostatic lesions were detected in all patients by both tracers with concordant PET-based T stage. Median SUV max of the dominant PSMA-positive prostatic lesions was not significantly different with 18 F-PSMA-1007 and 68 Ga-PSMA-11 (19.9 vs 19.4, P = 0.127, n = 40). Prostatic miPSMA scores were similar in 31/40 (77.5%) patients with both tracers (weighted κ = 0.71). In 23/40 (57.5%) patients, regional lymph nodes (n = 171) were detected by both tracers. Few additional PET-positive regional lymph nodes (n = 3) were exclusively detected by 18 F-PSMA in 2 patients without altering PET-based N stage. Extraregional lymph nodes (n = 123 in 17/40 patients) and visceral metastatic lesions (n = 18 in 3/40 patients) were detected concordantly by both tracers. PET-positive marrow based and skeletal metastases (n = 71) were detected in 14/40 (35%) patients by both tracers. Few additional marrow and skeletal lesions (n = 7) were exclusively detected on 18 F-PSMA-1007 in 5/14 patients, potentially upstaging PET-based M stage in 2/5 patients. Both radiotracers showed excellent interreader agreement for region-wise detection of lesions. CONCLUSIONS: Our results suggest that 18 F-PSMA-1007 PET/CT is comparable to 68 Ga-PSMA-11 PET/CT in detecting primary and metastatic lesions of PCa.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chandekar KR, Singh H, Kumar R, et al. Comparison of 18 F-PSMA-1007 PET/CT With 68 Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer. Clin Nucl Med. 2022. PMID: 36240786. doi:10.1097/RLU.0000000000004430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。